Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Catecholamine neurotransmitter system
- Molecular classification
- Neurotransmitter system, Contains multiple molecular targets, including: G protein-coupled receptors (Dopamine receptors, Adrenergic receptors), Enzymes (e.g., Tyrosine hydroxylase, DOPA decarboxylase), Transporters (Dopamine transporter, Norepinephrine transporter; VMAT)
01
Overview
The **catecholamine neurotransmitter system** refers collectively to the set of neurotransmitters **dopamine, norepinephrine, and epinephrine**, their molecular biosynthetic and metabolic pathways, and their membrane receptors and transporters. These neurotransmitters play central roles in the regulation of mood, cognition, arousal, stress response, autonomic nervous system control, motor coordination, and metabolic processes. Disruption or dysregulation of the catecholamine system is implicated in a wide range of human diseases—particularly neurodegenerative, psychiatric, cardiovascular, and endocrine disorders. Drugs targeting elements of the catecholamine system are among the most widely used in clinical medicine, including treatments for depression, hypertension, heart failure, Parkinson’s disease, and ADHD[1][4][5][6][7].
- Other names
- Catecholaminergic systemCatecholamine systemCatecholaminergic neurotransmission(Broadly: monoaminergic system, though this includes serotonin as well)
02
Mechanism of action
Agonism or antagonism at dopamine or adrenergic receptors Reuptake inhibition (DAT, NET) Inhibition of breakdown (MAO, COMT inhibitors) Modulation of transmitter synthesis or release
03
Biological functions
Signal transductionNeuromodulationRegulation of mood, reward, arousal, motor functionFight-or-flight responseCardiovascular, metabolic, and endocrine regulation
04
Disease associations
Neurodegenerative disease (Parkinson's disease—dopamine dysfunction)Psychiatric disorders (depression, schizophrenia—dopamine and/or norepinephrine dysfunction)Cardiovascular disease (hypertension, arrhythmias—adrenergic dysfunction)Neuroendocrine tumors (pheochromocytoma—catecholamine hypersecretion)
05
Safety considerations
Hypertension (adrenergic overactivation)Arrhythmias (adrenergic drugs or tumor)Neuropsychiatric side effects (dopaminergic or adrenergic drugs)Dyskinesia (dopaminergic overstimulation, e.g., in Parkinson's disease treatment)
06
Interacting drugs
Levodopa (dopamine precursor, Parkinson's)
5 more in the full profile.
07
Biomarkers
Plasma or urinary catecholamines (for pheochromocytoma and neuroendocrine tumors)DOPA metabolites (e.g., homovanillic acid, vanillylmandelic acid; for neurological disease monitoring)
Beyond the preview
Go deeper on Catecholamine neurotransmitter system.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Catecholamine neurotransmitter system.